HARROW INC (HROW) Stock News

Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients

Where Harrow Stands With Analysts

Harrow (HROW) Q4 Earnings and Revenues Top Estimates

Harrow (HROW) delivered earnings and revenue surprises of 127.27% and 1.24%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Mentions: ELV

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL

S&P 500 Down 1%; Sarepta Therapeutics Shares Plunge

Mentions: IHS SRPT HUYA FINV ...

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

Harrow Launches VEVYE® Access for All

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery

Harrow Announces Participation in Upcoming Investor Conferences